Autologous Peripheral Blood Mononuclear Cell Recognition of Autologous Proliferating Tumor Cells in the Context of a Patient-Specific Vaccine Trial

<table>Peripheral blood lymphocytes were placed in the wells of ELISPOT plates in quadruplicate under three separate conditions:  unstimulated (−Stm), stimulated with 3000 IU/mL IL-2, 2 <i>μ</i>g/mL PHA, and 5 <i>μ</i>g/mL OKT3 (+Stm), or combined with autologous tumor cells at a ratio of 1 : 2 (+ATC).  After 48 hours, IFN-<i>γ</i> secretion was determined as per manufacturer’s instructions. Numbers indicate spots counted by automated counter.</table>

BioMed Research International

fig1

Figure 1

Figure 1: Autologous Peripheral Blood Mononuclear Cell Recognition of Autologous Proliferating Tumor Cells in the Context of a Patient-Specific Vaccine Trial 

Figure 1 | Autologous Peripheral Blood Mononuclear Cell Recognition of Autologous Proliferating Tumor Cells in the Context of a Patient-Specific Vaccine Trial 